Survival following early-stage colon cancer: An ACCENT-based comparison of patients versus a matched international general population

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 950-958

  Renfro, Lindsay A ^a   Grothey, A ^a   Kerr, D ^b,m   Haller, D G ^c,n   Andre T ^d,e   Van Cutsem, E ^f   Saltz, L ^g   Labianca, R ^h,q   Loprinzi, C L ^a   Alberts, S R ^a,a   Schmoll, H ⁱ   Twelves, C ^j,y   Yothers, G ^k,k   Sargent, D J ^a   Green, E ^a   Shi, Q ^a   Renfro, L A ^a   O'Connell, M J ^k   Wolmark, N ^k   Gramont, A de ^l   Gray, R ^m   Guthrie, K ^o   Buyse, M ^p   Seitz, J F ^r   O'Callaghan, C J ^s   Francini, G ^t   Catalano, P J ^u   Blanke, C D ^v   Andre, T ^d   Goldberg, R M ^w   Benson, A ^x   Sirzen, F ^z   Cisar, L ^aa   Cutsem, E Van ^f   more..

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HÔPITAL SAINT ANTOINE   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h Ospedale Papa Giovanni XXIII   (Italy)

ⁱ MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^j ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^k NSABP Foundation Inc   (United States)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m QUASAR Quick and Simple and Reliable Collaborative Group   (United Kingdom)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^p INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^q OSPEDALI RIUNITI   (Italy)

^r AIX MARSEILLE UNIVERSITY   (France)

^s QUEEN S UNIVERSITY   (Canada)

^t UNIVERSITY OF SIENA   (Italy)

^u Eastern Cooperative Oncology Group (ECOG)   (United States)

^v OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^w OHIO STATE UNIVERSITY   (United States)

^x NORTHWESTERN UNIVERSITY   (United States)

^y UNIVERSITY OF BRADFORD   (United Kingdom)

^z F HOFFMANN LA ROCHE LTD   (Switzerland)

^aa PFIZER INC   (United States)

more..

Author keywords

Early stage colon cancer; Individual patient data; Long term survival; Meta analysis; Oxaliplatin chemotherapy; Population

Indexed keywords

AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; EARLY CANCER; FEMALE; HEALTH CARE QUALITY; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; CASE CONTROL STUDY; COLONIC NEOPLASMS; DISEASE FREE SURVIVAL; EARLY CANCER DIAGNOSIS; FACTUAL DATABASE; KAPLAN MEIER METHOD; META ANALYSIS; METASTASIS; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

CASE-CONTROL STUDIES; COLONIC NEOPLASMS; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929083369     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv073     Document Type: Article

References (18)

1. CDC-Colorectal Cancer Statistics. Centers for Disease Control and Prevention. Atlanta (GA). http://www.cdc.gov/cancer/colorectal/statistics/(15 April 2014, date last accessed).
2. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
3. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
4. Shi Q, Andre T, Grothey A et al. for the Adjuvant Colon Cancer Endpoints (ACCENT) Group. Comparison of outcomes after 5-fulorouracil-based adjuvant therapy for stage II and III colon cancer between 1978-1995 and 1996-2007: evidence of stage migration from the ACCENT dataset. J Clin Oncol 2013; 31: 3656-3663.
5. Sargent DJ, Sobrero A, Grothey A et al. Evidence for cure by adjuvant chemotherapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27: 872-877.
6. Jensen AB, Larsen M, Gislum M et al. Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study. Am J Gastroenterol 2006; 101: 1283-1287.
7. Majek O, Gondos A, Jansen L et al. for the GEKID Cancer Survival Working Group. Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. PLoS ONE 2013; 8: e68077.
8. Gatta G, Ciccolallo L, Capocaccia R et al. for the EUROCARE Working Group. Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur J Cancer 2003; 39: 2214-2222.
9. Allemani C, Rachet B, Weir HK et al. Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open 2013; 3: e003055.
10. Sanoff HK, Carpenter WR, Sturmer T et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 2012; 30: 2624-2634.
11. Chang GJ, Hu C, Eng C et al. Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol 2009; 27: 5938-5943.
12. Zamboni BA, Yothers G, Choi M et al. Conditional survival and choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol 2010; 28: 2544-2548.
13. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-8670.
14. Sargent DJ, Shi Q, Yothers G et al. Two or three year disease free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803. Eur J Cancer 2011; 47: 990-996.
15. Finkelstein DM, Muzikansky A, Schoenfeld DA. Commentary: comparing survival of a sample to that of a standard population. J Natl Cancer Inst 2003; 95: 1434-1439.
16. Human Mortality Database. A Collaboration of the University of California at Berkeley and the Max Planck Institute: Rostock, Germany. www.mortality.og. (16 May 2014, date last accessed).
17. Life Expectancy: Life Tables by Country. World Health Organization. http://apps.who.int/gho/data/node.main.692?lang=en. (16 May 2014, date last accessed).
18. O'Connell JB, Maggard MA, Liu JH et al. Do young colon cancer patients have worse outcomes? World J Surg 2004; 28: 558-562.